News Select Year All Years 2026 (21) 2025 (37) 2024 (31) 2023 (31) 2022 (35) 2021 (28) 2020 (36) 2019 (46) 2018 (51) 2017 (34) 2016 (26) 2015 (42) 2014 (30) 2013 (26) 2012 (23) 2011 (28) 2010 (36) 2009 (39) 2008 (55) 2007 (50) Clinical Trials Select Clinical Trial AWARE-1 (21) BRACELET-1 (10) GOBLET (35) Search … September 8, 2025 Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions September 2, 2025 Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors August 28, 2025 Oncolytics Biotech® Announces Upcoming Investor Conferences in September August 11, 2025 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders August 8, 2025 Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep August 8, 2025 Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange August 5, 2025 Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results July 29, 2025 Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End July 23, 2025 Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential July 22, 2025 Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules Newer Page 4 of 71 Older